MX2020003660A - Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas. - Google Patents

Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.

Info

Publication number
MX2020003660A
MX2020003660A MX2020003660A MX2020003660A MX2020003660A MX 2020003660 A MX2020003660 A MX 2020003660A MX 2020003660 A MX2020003660 A MX 2020003660A MX 2020003660 A MX2020003660 A MX 2020003660A MX 2020003660 A MX2020003660 A MX 2020003660A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
microbial infections
acid derivatives
gluconic acid
Prior art date
Application number
MX2020003660A
Other languages
English (en)
Spanish (es)
Inventor
Olov Sterner
Ulf Ellervik
Helena Strevens
Sophie Manner
Original Assignee
Gedea Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech Ab filed Critical Gedea Biotech Ab
Publication of MX2020003660A publication Critical patent/MX2020003660A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126Acids containing more than four carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • C07D307/33Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020003660A 2017-10-06 2018-10-05 Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas. MX2020003660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17195192 2017-10-06
PCT/EP2018/077129 WO2019068862A1 (en) 2017-10-06 2018-10-05 GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS

Publications (1)

Publication Number Publication Date
MX2020003660A true MX2020003660A (es) 2020-08-03

Family

ID=60185986

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003660A MX2020003660A (es) 2017-10-06 2018-10-05 Derivados de acido gluconico para ser usados en el tratamiento y/o prevencion de infecciones microbianas.

Country Status (21)

Country Link
US (3) US11612584B2 (enExample)
EP (1) EP3691625B1 (enExample)
JP (1) JP7424636B2 (enExample)
KR (1) KR102650182B1 (enExample)
CN (1) CN111182895B (enExample)
AU (1) AU2018346361B2 (enExample)
BR (1) BR112020006931A2 (enExample)
CA (1) CA3078451A1 (enExample)
CL (1) CL2020000859A1 (enExample)
EA (1) EA202090750A1 (enExample)
ES (1) ES3017694T3 (enExample)
HU (1) HUE070746T2 (enExample)
IL (1) IL273297B2 (enExample)
MX (1) MX2020003660A (enExample)
MY (1) MY205944A (enExample)
PH (1) PH12020550222A1 (enExample)
PL (1) PL3691625T3 (enExample)
SG (1) SG11202002494WA (enExample)
UA (1) UA126590C2 (enExample)
WO (1) WO2019068862A1 (enExample)
ZA (1) ZA202001605B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3017694T3 (en) 2017-10-06 2025-05-13 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY208388A (en) 2019-04-05 2025-05-06 Gedea Biotech Ab Vaginal tablet formulation
CN114751878B (zh) * 2022-03-29 2023-06-16 青岛农业大学 一种BcTol1基因靶向剂及其应用
WO2024261110A1 (en) * 2023-06-22 2024-12-26 Gedea Biotech Ab Compositions for promoting growth of lactobacillus crispatus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278868B1 (it) 1995-10-27 1997-11-28 Sanitaria Scaligera Spa Metodo per l'ottenimento di un materiale riassorbibile atto ad essere utilizzato come elemento di rivestimento per la prevenzione di
AUPP839499A0 (en) 1999-01-29 1999-02-25 Australian National University, The A method for controlling plant pathogens, and agents useful for same
JP3745612B2 (ja) 2000-10-31 2006-02-15 西川ゴム工業株式会社 ポリヒドロキシカルボン酸の製造方法
US20030017207A1 (en) 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
CA2487270C (en) 2002-06-21 2010-10-26 The Procter & Gamble Company Antimicrobial compositions, products and methods employing same
US7569530B1 (en) 2003-06-20 2009-08-04 The Procter & Gamble Company Antimicrobial compositions, products and methods employing same
US7547454B2 (en) * 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050260243A1 (en) * 2004-04-26 2005-11-24 The Procter & Gamble Company Method of treating microbial plant diseases
US20050271711A1 (en) 2004-04-26 2005-12-08 The Procter & Gamble Company Therapeutic antimicrobial compositions and methods
AU2006209263A1 (en) 2005-09-12 2007-03-29 Mcneil-Ppc, Inc. Anhydrous composition containing an acid-acid buffer system
US20070059278A1 (en) 2005-09-12 2007-03-15 Nawaz Ahmad Anhydrous composition containing an acid-acid buffer system
US20080058421A1 (en) * 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
WO2008108834A2 (en) * 2006-11-09 2008-09-12 Northwestern University Inhibitors of the mevalonate pathway of streptococcus pneumoniae
JP2008283893A (ja) * 2007-05-16 2008-11-27 Sumitomo Chemical Co Ltd 家禽用コクシジウム感染抑制剤及びそれを用いたコクシジウム感染抑制方法
US20100285095A1 (en) * 2009-05-05 2010-11-11 Kimberly Ann Nemeth Hygiene Article Having Calcium Sugar Acid Salt
CN102070774B (zh) 2010-11-25 2012-08-22 华南师范大学 单糖或其糖醇与乳酸的共聚物的制备方法
MX2013012745A (es) 2011-05-02 2014-12-05 Aptalis Pharmatech Inc Composiciones en forma de comprmido de disolución rápida para administración vaginal.
MY172685A (en) 2013-11-08 2019-12-10 Suzhou Osel Bio Pharm Co Ltd A lactobacillus crispatus and application thereof
DK178786B1 (en) * 2015-03-11 2017-02-06 Dantrace-Danfeed Ivs Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus
DK3439633T3 (da) * 2016-04-06 2021-12-20 Gedea Biotech Ab Glucono delta-lacton til behandling af vaginale svampeinfektioner
JP7219712B2 (ja) 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
KR101841976B1 (ko) 2017-06-07 2018-05-14 조영진 식물 추출물을 포함하는 항진균 및 항균 조성물
ES3017694T3 (en) 2017-10-06 2025-05-13 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY208388A (en) 2019-04-05 2025-05-06 Gedea Biotech Ab Vaginal tablet formulation

Also Published As

Publication number Publication date
KR102650182B1 (ko) 2024-03-21
US20200253925A1 (en) 2020-08-13
SG11202002494WA (en) 2020-04-29
PH12020550222A1 (en) 2021-02-15
BR112020006931A2 (pt) 2020-10-06
UA126590C2 (uk) 2022-11-02
CA3078451A1 (en) 2019-04-11
PL3691625T3 (pl) 2025-05-12
JP2020536862A (ja) 2020-12-17
ES3017694T3 (en) 2025-05-13
EP3691625A1 (en) 2020-08-12
CN111182895A (zh) 2020-05-19
IL273297B1 (en) 2024-02-01
CL2020000859A1 (es) 2020-10-02
AU2018346361B2 (en) 2024-07-25
US11612584B2 (en) 2023-03-28
ZA202001605B (en) 2023-12-20
AU2018346361A1 (en) 2020-05-14
JP7424636B2 (ja) 2024-01-30
US12226396B2 (en) 2025-02-18
US20230181523A1 (en) 2023-06-15
EP3691625B1 (en) 2025-02-19
HUE070746T2 (hu) 2025-07-28
MY205944A (en) 2024-11-21
US20250144070A1 (en) 2025-05-08
EP3691625C0 (en) 2025-02-19
WO2019068862A1 (en) 2019-04-11
EA202090750A1 (ru) 2020-11-11
CN111182895B (zh) 2024-05-14
IL273297B2 (en) 2024-06-01
KR20200060413A (ko) 2020-05-29
IL273297A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CL2020001752A1 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa.
JOP20150301B1 (ar) بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX354123B (es) Composición antiséptica oral para tratamiento de mucositis oral.
DOP2016000253A (es) Nuevos compuestos
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2020001147A1 (es) Compuestos antibacterianos
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
BR122020011180B8 (pt) formulações injetáveis de compostos de tetraciclina
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CL2017002449A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ